GAVI Alliance pours $100M into meningitis vaccine

The GAVI Alliance has committed $100 million to support a meningitis A vaccine called MenAfriVac developed by Seattle-based PATH. The vaccine, which was developed with the help of a $70 million donation from the Bill and Melinda Gates Foundation, has already been introduced in Burkina Faso, Mali and Niger. The funding includes $72.6 million to purchase MenAfriVac vaccines and $27.6 million for operational costs. Release

Suggested Articles

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.

Takeda has spent considerable resources on its phase 3 dengue vaccine, and now data show the shot was 80% effective in preventing dengue.